Opinion
Entresto, inpatient therapy, and surrogate markers
One overriding factor behind the slow uptake of Entresto for heart failure may be the cost of the drug compared to enalapril.
Opinion
Are guidelines relevant?
RCTs represent a very special subset of any disease process but they are the best we can do.
Opinion
Who’s increasing health care costs? Not us!
Community leadership has been minimized, and where it exists, it is under constant pressure to make a profit.
Opinion
Medical ethics and economics
It’s up to physicians to build an ethical wall between interests in clinical research.
News
Heart cell transplant rejections
Piero Anversa’s fraudulent research led to an NIH study in humans that is still ongoing.
Opinion
I’M NOT A PROVIDER
Health care isn’t a commodity, and patients aren’t customers. We’re not talking about shoes.
News
On cardiology training
I recently received a letter from a former fellow who completed his training almost 25 years ago, thanking me for guiding him through his...
News
‘If this is an emergency, call 911’
Or, don’t even try speaking directly your doctor.
Opinion
Beta-blocker therapy post AMI
Stick with beta-blocker therapy until evidence shows why not to use it.
Opinion
CMS clinical trials raise cardiac mortality
Health agencies should take their cues from randomized clinical trial designs to avoid unintended consequences.
Article
PCI or CABG in the high-risk patient
The recent report from the SYNTAX trials should give pause to our interventionalist colleagues embarking on multiple angioplasty and stenting...
Article
TOPCAT, a third time around
TOPCAT is back again, having randomized its first patient with heart failure with preserved ejection fraction (HFpEF) almost 10 years ago for its...
News
The new heart failure: A call for new research initiatives
Progress in treating ischemic heart disease has resulted in more patients with heart failure, and we must work to develop more effective heart...